Suppr超能文献

食管癌放疗后因心脏病导致的死亡风险增加。

Increased risk of death due to heart disease after radiotherapy for esophageal cancer.

作者信息

Frandsen Jonathan, Boothe Dustin, Gaffney David K, Wilson Brent D, Lloyd Shane

机构信息

1 Radiation Oncology Department, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT 84112, USA ; 2 Division of Cardiology, University of Utah, University Hospital, Salt Lake City, UT 84112, USA.

出版信息

J Gastrointest Oncol. 2015 Oct;6(5):516-23. doi: 10.3978/j.issn.2078-6891.2015.040.

Abstract

OBJECTIVE

To evaluate the risk of heart disease related death (HDRD) following radiation therapy (RT) for esophageal cancer (EC).

METHODS

Using the Surveillance, Epidemiology, and End Results (SEER) database, two cohorts of patients with EC were created: (I) patients who received RT with their initial therapy; and (II) those who did not. Heart disease specific survival (HDSS) was analyzed using Kaplan-Meier methods. Cox proportional-hazards regression methods were used for univariate and multivariate analyses.

RESULTS

We identified 40,778 patients with EC. A total of 26,377 patients received RT and 14,401 did not. HDSS analysis revealed increased risk of HDRD in those receiving RT (P<0.05), with an absolute risk of HDRD of 2.8%, 5.3% and 9.4% at 5-, 10- and 20-year, respectively. Log rank test of HDSS revealed the risk of HDRD became significant at 8 months (P<0.05). The following were associated with HDRD: RT, age, race, stage at presentation, time period of diagnosis, and known comorbid condition keeping one from esophagectomy. On multivariate analysis, RT remained predictive of HDRD [hazard ratio (HR) 1.46, P<0.05]. When considering only candidates for definitive therapy, RT remained predictive of HDRD on univariate (HR 1.53, P<0.0001) and multivariate (HR 1.62, P<0.0001) analyses.

CONCLUSIONS

The use of RT leads to increased risk of HDRD that is detectable as early as eight months from diagnosis. More research is needed to define optimal dose volume parameters to prevent cardiac death. Consideration should be given to this risk in relation to prognosis and the expected benefits of RT.

摘要

目的

评估食管癌(EC)放射治疗(RT)后心脏病相关死亡(HDRD)的风险。

方法

利用监测、流行病学和最终结果(SEER)数据库,创建了两组EC患者队列:(I)初始治疗接受RT的患者;(II)未接受RT的患者。采用Kaplan-Meier方法分析心脏病特异性生存率(HDSS)。使用Cox比例风险回归方法进行单变量和多变量分析。

结果

我们识别出40778例EC患者。共有26377例患者接受了RT,14401例未接受。HDSS分析显示,接受RT的患者发生HDRD的风险增加(P<0.05),5年、10年和20年时HDRD的绝对风险分别为2.8%、5.3%和9.4%。HDSS的对数秩检验显示,HDRD风险在8个月时变得显著(P<0.05)。以下因素与HDRD相关:RT、年龄、种族、就诊时分期、诊断时间段以及因已知合并症而无法进行食管切除术。多变量分析时,RT仍然是HDRD的预测因素[风险比(HR)1.46,P<0.05]。仅考虑确定性治疗的候选患者时,RT在单变量分析(HR 1.53,P<0.0001)和多变量分析(HR 1.62,P<0.0001)中仍然是HDRD的预测因素。

结论

RT的使用导致HDRD风险增加,最早在诊断后8个月即可检测到。需要更多研究来确定预防心脏死亡的最佳剂量体积参数。应结合预后和RT的预期益处考虑这一风险。

相似文献

1
Increased risk of death due to heart disease after radiotherapy for esophageal cancer.
J Gastrointest Oncol. 2015 Oct;6(5):516-23. doi: 10.3978/j.issn.2078-6891.2015.040.
4
Neoadjuvant radiotherapy provided survival benefit compared to adjuvant radiotherapy for hepatocellular carcinoma.
ANZ J Surg. 2018 Oct;88(10):E718-E724. doi: 10.1111/ans.14387. Epub 2018 Feb 5.
8
Radiation therapy improves survival for unresectable postpneumonectomy lung tumors.
J Surg Res. 2018 Jul;227:60-66. doi: 10.1016/j.jss.2018.02.015. Epub 2018 Mar 12.
9
Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study.
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):449-55. doi: 10.1016/j.ijrobp.2008.04.022. Epub 2008 Jun 4.

引用本文的文献

5
Development and validation of a nomogram to predict cardiac death after radiotherapy for esophageal cancer.
Cancer Innov. 2023 Sep 1;2(5):391-404. doi: 10.1002/cai2.89. eCollection 2023 Oct.
7
Cardiovascular disease related death among patients with esophagus cancer: A population-based competing risk analysis.
Front Oncol. 2022 Sep 15;12:976711. doi: 10.3389/fonc.2022.976711. eCollection 2022.
8
Proton Beam Therapy for Esophageal Cancer.
Cancers (Basel). 2022 Aug 22;14(16):4045. doi: 10.3390/cancers14164045.
9
Radiation-induced coronary artery disease: a difficult clinical conundrum.
Clin Med (Lond). 2022 May;22(3):251-256. doi: 10.7861/clinmed.2021-0600.

本文引用的文献

1
Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.
J Clin Oncol. 2014 Feb 10;32(5):385-91. doi: 10.1200/JCO.2013.51.2186. Epub 2014 Jan 13.
2
Risk of ischemic heart disease in women after radiotherapy for breast cancer.
N Engl J Med. 2013 Mar 14;368(11):987-98. doi: 10.1056/NEJMoa1209825.
3
Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer.
Br J Cancer. 2013 Jan 15;108(1):179-82. doi: 10.1038/bjc.2012.575. Epub 2012 Dec 20.
4
Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer.
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1078-85. doi: 10.1016/j.ijrobp.2012.02.015. Epub 2012 Aug 3.
5
Preoperative chemoradiotherapy for esophageal or junctional cancer.
N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.
8
Radiation dose-volume effects in the heart.
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S77-85. doi: 10.1016/j.ijrobp.2009.04.093.
9
Use of normal tissue complication probability models in the clinic.
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9. doi: 10.1016/j.ijrobp.2009.07.1754.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验